Atalanta Therapeutics reports the suppression of seizures in a genetic mouse model of KCNT1 epilepsy by reducing Kcnt1 transcript with divalent small interfering RNA (siRNA), an emerging variant of oligonucleotide technology developed for the central nervous system. They plan to advance their KCNT1 program toward an IND submission this year, with the goal of initiating a Phase 1 clinical trial if approved by regulatory authorities. Read the science here, and the news release here.
Footer
